课题基金 / 基金详情

ComPASS Collective for Community Engagement (C3E)

ComPASS Collective for Community Engagement (C3E)
ComPASS 社区参与集体 (C3E)
批准号:
10903370
负责人:
Gordon R Bernard
金额:
$70.0万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-11 至 2024-02-29

项目摘要

项目成果

Gordon R Bernard的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functional and integrated clinical and translational (C&T) research infrastructure that has raised the quality and scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry, the nation's oldest historically black academic health science institution. VICTR will contribute to the mission of the CTSA program while leveraging unique resources and expertise within VICTR's Hub and elevating the role of health equity in C&T research with these new aims: 1) Leverage VICTR's strong collaborative energy to enhance team science methodologies, integrate community engagement principles for all stages of research, and implement programs designed to support health equity in research; 2) Develop and share multi-dimensional data organization methods and informatics tools to promulgate innovation, efficiency, quality, and equity in research; 3) Ensure the translational science workforce is diverse and has the skills, knowledge, and resources necessary to advance translation of discoveries within a health equity framework; 4) Support the efficiency, quality, representativeness, and impact of local studies and `raise the bar' for acceptable scientific standards in research conduct; 5) Support the efficiency, quality, representativeness, and impact of multi-site clinical trials by building and disseminating streamlining programs and promoting novel trial designs; and 6) Utilize unique institutional capabilities to enable the conduct of pragmatic trials during healthcare operations and repurpose existing drugs for new indications.
期刊论文(480)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.isci.2021.103602
发表时间: 2022-01-21
期刊: iScience
影响因子: 5.8
作者: [Gilchuk P, Thomsen I, Yoder S, Brady E, Chappell JD, Stevens LJ, Denison MR, Sutton RE, Chen RE, VanBlargan LA, Suryadevara N, Zost SJ, Schmitz J, Pulley JM, Diamond MS, Rhoads JP, Bernard GR, Self WH, Rice TW, Wheeler AP, Crowe JE Jr, Carnahan RH]
通讯作者: Carnahan RH
DOI: 10.1080/00207144.2022.2096455
发表时间: 2022-07
期刊: INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL HYPNOSIS
影响因子: 1.7
作者: [McKernan, Lindsey C., Finn, Michael T. M., Crofford, Leslie J., Kelly, A. Gracie, Patterson, David R., Jensen, Mark P.]
通讯作者: Jensen, Mark P.
DOI: 10.1093/infdis/jiac442
发表时间: 2023-05-12
期刊: The Journal of infectious diseases
影响因子: --
作者: []
通讯作者:
DOI: 10.1016/j.neubiorev.2017.08.018
发表时间: 2018-01
期刊: Neuroscience and biobehavioral reviews
影响因子: 8.2
作者: [Gandelman JA, Newhouse P, Taylor WD]
通讯作者: Taylor WD
266
    Engaging Cooperative Sites for Trial Acceleration, Trust, Innovation, and Capability (ECSTATIC)
    Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency (CAPSTONE)
    Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
    Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
    海外基金